Summary

The global Liposome Development Service market size was US$ 1217 million in 2024 and is forecast to a readjusted size of US$ 2079 million by 2031 with a CAGR of 8.1% during the forecast period 2025-2031.
Liposomes are a type of nano-sized phospholipid bubbles, which have attracted much attention as potential drug carriers. Liposomes are highly biocompatible and easy to control in vivo and can be loaded with a broad variety of drugs, DNA, and diagnostic agents. To date, a variety of liposomal drugs are under development and some of them are already approved for clinical use.

Market Driver
The liposome development service market is driven by the growing demand for advanced drug delivery systems that enhance the bioavailability, efficacy, and safety of therapeutics. Liposomes, being biocompatible and capable of targeted drug delivery, are increasingly used in the development of treatments for cancer, infectious diseases, and vaccines. Additionally, the rise in biologics and personalized medicine, coupled with advancements in nanotechnology, supports the growth of the liposome development service market.

Market Challenge
Despite its potential, the liposome development service market faces challenges such as high production costs and complex manufacturing processes that require specialized expertise and facilities. Regulatory hurdles in the approval of liposome-based therapies and the potential for stability issues during storage and transportation further constrain the market's growth. These factors create barriers, particularly for smaller companies with limited resources.

Global key players of liposome development service include Precision NanoSystems, Evonik, Merck KGaA, Genevant Sciences, Exelead, etc. The top two players hold a share over 52%. North America is the largest market, has a share about 61%, followed by Europe and Asia-Pacific, with share 26% and 11%, separately. In terms of product type, Lipid Nanoparticles is the largest segment, occupied for a share of 62%, and in terms of application, Commercial has a share about 86 percent.
The global Liposome Development Service market is strategically segmented by company, region (country), by Type, and by Application. This report empowers stakeholders to capitalize on emerging opportunities, optimize product strategies, and outperform competitors through data-driven insights on revenue and forecasts across regions, by Type, and by Application for 2020-2031.

Market Segmentation
By Company:
Precision NanoSystems
Evonik
Merck KGaA
Genevant Sciences
Exelead
Avanti Polar Lipids
Nippon Fine Chemical
Lipoid
Polymun Scientific
Corden Pharma
Acuitas Therapeutics
Creative Biolabs
Creative Biostructure
T&T Scientific
FormuMax Scientific
PlantaCorp
CD Bioparticles
By Type: (Dominant Segment vs High-Margin Innovation)
Liposomes
Lipid Nanoparticles
By Application: (Core Demand Driver vs Emerging Opportunity)
Preclinical
Clinical
Commercial
By Region
Macro-Regional Analysis: Market Size & Growth Forecasts
- North America
- Europe
- Asia-Pacific
- South America
- Middle East & Africa
Micro-Local Market Deep Dive: Strategic Insights
- Competitive Landscape: Player dominance vs. disruptors (e.g., Precision NanoSystems in Europe)
- Emerging Product Trends: Liposomes adoption vs. Lipid Nanoparticles premiumization
- Demand-Side Dynamics: Preclinical growth in China vs. Clinical potential in North America
- Localized Consumer Needs: Regulatory hurdles in EU vs. price sensitivity in India
Focus Markets:
North America
Europe
Asia-Pacific
Latin America
Middle East & Africa
(Additional regions can be customized based on client needs.)

Chapter Outline
Chapter 1: Report scope, executive summary, and market evolution scenarios (short/mid/long term).
Chapter 2: Quantitative analysis of Liposome Development Service market size and growth potential at global, regional, and country levels.
Chapter 3: Competitive benchmarking of manufacturers (revenue, market share, M&A, R&D focus).
Chapter 4: Type-based segmentation analysis – Uncovering blue ocean markets (e.g., Lipid Nanoparticles in China).
Chapter 5: Application-based segmentation analysis – High-growth downstream opportunities (e.g., Clinical in India).
Chapter 6: Regional revenue breakdown by company, type, application and customer.
Chapter 7: Key manufacturer profiles – Financials, product portfolios, and strategic developments.
Chapter 8: Market dynamics – Drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 9: Actionable conclusions and strategic recommendations.
Why This Report?
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Liposome Development Service value chain, addressing:
- Market entry risks/opportunities by region
- Product mix optimization based on local practices
- Competitor tactics in fragmented vs. consolidated markets

ページTOPに戻る

Table of Contents

1 Report Overview
1.1 Study Scope
1.2 Market by Type
1.2.1 Global Market Size Growth by Type: 2020 VS 2024 VS 2031
1.2.2 Liposomes
1.2.3 Lipid Nanoparticles
1.3 Market by Application
1.3.1 Global Market Share by Application: 2020 VS 2024 VS 2031
1.3.2 Preclinical
1.3.3 Clinical
1.3.4 Commercial
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Liposome Development Service Market Perspective (2020-2031)
2.2 Global Market Size by Region: 2020 VS 2024 VS 2031
2.3 Global Liposome Development Service Revenue Market Share by Region (2020-2025)
2.4 Global Liposome Development Service Revenue Forecast by Region (2026-2031)
2.5 Major Region and Emerging Market Analysis
2.5.1 North America Liposome Development Service Market Size and Prospective (2020-2031)
2.5.2 Europe Liposome Development Service Market Size and Prospective (2020-2031)
2.5.3 Asia-Pacific Liposome Development Service Market Size and Prospective (2020-2031)
2.5.4 Latin America Liposome Development Service Market Size and Prospective (2020-2031)
2.5.5 Middle East & Africa Liposome Development Service Market Size and Prospective (2020-2031)
3 Breakdown Data by Type
3.1 Global Liposome Development Service Historic Market Size by Type (2020-2025)
3.2 Global Liposome Development Service Forecasted Market Size by Type (2026-2031)
3.3 Different Types Liposome Development Service Representative Players
4 Breakdown Data by Application
4.1 Global Liposome Development Service Historic Market Size by Application (2020-2025)
4.2 Global Liposome Development Service Forecasted Market Size by Application (2026-2031)
4.3 New Sources of Growth in Liposome Development Service Application
5 Competition Landscape by Players
5.1 Global Top Players by Revenue
5.1.1 Global Top Liposome Development Service Players by Revenue (2020-2025)
5.1.2 Global Liposome Development Service Revenue Market Share by Players (2020-2025)
5.2 Global Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
5.3 Players Covered: Ranking by Liposome Development Service Revenue
5.4 Global Liposome Development Service Market Concentration Analysis
5.4.1 Global Liposome Development Service Market Concentration Ratio (CR5 and HHI)
5.4.2 Global Top 10 and Top 5 Companies by Liposome Development Service Revenue in 2024
5.5 Global Key Players of Liposome Development Service Head office and Area Served
5.6 Global Key Players of Liposome Development Service, Product and Application
5.7 Global Key Players of Liposome Development Service, Date of Enter into This Industry
5.8 Mergers & Acquisitions, Expansion Plans
6 Region Analysis
6.1 North America Market: Players, Segments and Downstream
6.1.1 North America Liposome Development Service Revenue by Company (2020-2025)
6.1.2 North America Market Size by Type
6.1.2.1 North America Liposome Development Service Market Size by Type (2020-2025)
6.1.2.2 North America Liposome Development Service Market Share by Type (2020-2025)
6.1.3 North America Market Size by Application
6.1.3.1 North America Liposome Development Service Market Size by Application (2020-2025)
6.1.3.2 North America Liposome Development Service Market Share by Application (2020-2025)
6.1.4 North America Market Trend and Opportunities
6.2 Europe Market: Players, Segments and Downstream
6.2.1 Europe Liposome Development Service Revenue by Company (2020-2025)
6.2.2 Europe Market Size by Type
6.2.2.1 Europe Liposome Development Service Market Size by Type (2020-2025)
6.2.2.2 Europe Liposome Development Service Market Share by Type (2020-2025)
6.2.3 Europe Market Size by Application
6.2.3.1 Europe Liposome Development Service Market Size by Application (2020-2025)
6.2.3.2 Europe Liposome Development Service Market Share by Application (2020-2025)
6.2.4 Europe Market Trend and Opportunities
6.3 Asia-Pacific Market: Players, Segments and Downstream
6.3.1 Asia-Pacific Liposome Development Service Revenue by Company (2020-2025)
6.3.2 Asia-Pacific Market Size by Type
6.3.2.1 Asia-Pacific Liposome Development Service Market Size by Type (2020-2025)
6.3.2.2 Asia-Pacific Liposome Development Service Market Share by Type (2020-2025)
6.3.3 Asia-Pacific Market Size by Application
6.3.3.1 Asia-Pacific Liposome Development Service Market Size by Application (2020-2025)
6.3.3.2 Asia-Pacific Liposome Development Service Market Share by Application (2020-2025)
6.3.4 Asia-Pacific Market Trend and Opportunities
6.4 Latin America Market: Players, Segments and Downstream
6.4.1 Latin America Liposome Development Service Revenue by Company (2020-2025)
6.4.2 Latin America Market Size by Type
6.4.2.1 Latin America Liposome Development Service Market Size by Type (2020-2025)
6.4.2.2 Latin America Liposome Development Service Market Share by Type (2020-2025)
6.4.3 Latin America Market Size by Application
6.4.3.1 Latin America Liposome Development Service Market Size by Application (2020-2025)
6.4.3.2 Latin America Liposome Development Service Market Share by Application (2020-2025)
6.4.4 Latin America Market Trend and Opportunities
6.5 Middle East & Africa Market: Players, Segments and Downstream
6.5.1 Middle East & Africa Liposome Development Service Revenue by Company (2020-2025)
6.5.2 Middle East & Africa Market Size by Type
6.5.2.1 Middle East & Africa Liposome Development Service Market Size by Type (2020-2025)
6.5.2.2 Middle East & Africa Liposome Development Service Market Share by Type (2020-2025)
6.5.3 Middle East & Africa Market Size by Application
6.5.3.1 Middle East & Africa Liposome Development Service Market Size by Application (2020-2025)
6.5.3.2 Middle East & Africa Liposome Development Service Market Share by Application (2020-2025)
6.5.4 Middle East & Africa Market Trend and Opportunities
7 Key Players Profiles
7.1 Precision NanoSystems
7.1.1 Precision NanoSystems Company Details
7.1.2 Precision NanoSystems Business Overview
7.1.3 Precision NanoSystems Liposome Development Service Introduction
7.1.4 Precision NanoSystems Revenue in Liposome Development Service Business (2020-2025)
7.1.5 Precision NanoSystems Recent Development
7.2 Evonik
7.2.1 Evonik Company Details
7.2.2 Evonik Business Overview
7.2.3 Evonik Liposome Development Service Introduction
7.2.4 Evonik Revenue in Liposome Development Service Business (2020-2025)
7.2.5 Evonik Recent Development
7.3 Merck KGaA
7.3.1 Merck KGaA Company Details
7.3.2 Merck KGaA Business Overview
7.3.3 Merck KGaA Liposome Development Service Introduction
7.3.4 Merck KGaA Revenue in Liposome Development Service Business (2020-2025)
7.3.5 Merck KGaA Recent Development
7.4 Genevant Sciences
7.4.1 Genevant Sciences Company Details
7.4.2 Genevant Sciences Business Overview
7.4.3 Genevant Sciences Liposome Development Service Introduction
7.4.4 Genevant Sciences Revenue in Liposome Development Service Business (2020-2025)
7.4.5 Genevant Sciences Recent Development
7.5 Exelead
7.5.1 Exelead Company Details
7.5.2 Exelead Business Overview
7.5.3 Exelead Liposome Development Service Introduction
7.5.4 Exelead Revenue in Liposome Development Service Business (2020-2025)
7.5.5 Exelead Recent Development
7.6 Avanti Polar Lipids
7.6.1 Avanti Polar Lipids Company Details
7.6.2 Avanti Polar Lipids Business Overview
7.6.3 Avanti Polar Lipids Liposome Development Service Introduction
7.6.4 Avanti Polar Lipids Revenue in Liposome Development Service Business (2020-2025)
7.6.5 Avanti Polar Lipids Recent Development
7.7 Nippon Fine Chemical
7.7.1 Nippon Fine Chemical Company Details
7.7.2 Nippon Fine Chemical Business Overview
7.7.3 Nippon Fine Chemical Liposome Development Service Introduction
7.7.4 Nippon Fine Chemical Revenue in Liposome Development Service Business (2020-2025)
7.7.5 Nippon Fine Chemical Recent Development
7.8 Lipoid
7.8.1 Lipoid Company Details
7.8.2 Lipoid Business Overview
7.8.3 Lipoid Liposome Development Service Introduction
7.8.4 Lipoid Revenue in Liposome Development Service Business (2020-2025)
7.8.5 Lipoid Recent Development
7.9 Polymun Scientific
7.9.1 Polymun Scientific Company Details
7.9.2 Polymun Scientific Business Overview
7.9.3 Polymun Scientific Liposome Development Service Introduction
7.9.4 Polymun Scientific Revenue in Liposome Development Service Business (2020-2025)
7.9.5 Polymun Scientific Recent Development
7.10 Corden Pharma
7.10.1 Corden Pharma Company Details
7.10.2 Corden Pharma Business Overview
7.10.3 Corden Pharma Liposome Development Service Introduction
7.10.4 Corden Pharma Revenue in Liposome Development Service Business (2020-2025)
7.10.5 Corden Pharma Recent Development
7.11 Acuitas Therapeutics
7.11.1 Acuitas Therapeutics Company Details
7.11.2 Acuitas Therapeutics Business Overview
7.11.3 Acuitas Therapeutics Liposome Development Service Introduction
7.11.4 Acuitas Therapeutics Revenue in Liposome Development Service Business (2020-2025)
7.11.5 Acuitas Therapeutics Recent Development
7.12 Creative Biolabs
7.12.1 Creative Biolabs Company Details
7.12.2 Creative Biolabs Business Overview
7.12.3 Creative Biolabs Liposome Development Service Introduction
7.12.4 Creative Biolabs Revenue in Liposome Development Service Business (2020-2025)
7.12.5 Creative Biolabs Recent Development
7.13 Creative Biostructure
7.13.1 Creative Biostructure Company Details
7.13.2 Creative Biostructure Business Overview
7.13.3 Creative Biostructure Liposome Development Service Introduction
7.13.4 Creative Biostructure Revenue in Liposome Development Service Business (2020-2025)
7.13.5 Creative Biostructure Recent Development
7.14 T&T Scientific
7.14.1 T&T Scientific Company Details
7.14.2 T&T Scientific Business Overview
7.14.3 T&T Scientific Liposome Development Service Introduction
7.14.4 T&T Scientific Revenue in Liposome Development Service Business (2020-2025)
7.14.5 T&T Scientific Recent Development
7.15 FormuMax Scientific
7.15.1 FormuMax Scientific Company Details
7.15.2 FormuMax Scientific Business Overview
7.15.3 FormuMax Scientific Liposome Development Service Introduction
7.15.4 FormuMax Scientific Revenue in Liposome Development Service Business (2020-2025)
7.15.5 FormuMax Scientific Recent Development
7.16 PlantaCorp
7.16.1 PlantaCorp Company Details
7.16.2 PlantaCorp Business Overview
7.16.3 PlantaCorp Liposome Development Service Introduction
7.16.4 PlantaCorp Revenue in Liposome Development Service Business (2020-2025)
7.16.5 PlantaCorp Recent Development
7.17 CD Bioparticles
7.17.1 CD Bioparticles Company Details
7.17.2 CD Bioparticles Business Overview
7.17.3 CD Bioparticles Liposome Development Service Introduction
7.17.4 CD Bioparticles Revenue in Liposome Development Service Business (2020-2025)
7.17.5 CD Bioparticles Recent Development
8 Liposome Development Service Market Dynamics
8.1 Liposome Development Service Industry Trends
8.2 Liposome Development Service Market Drivers
8.3 Liposome Development Service Market Challenges
8.4 Liposome Development Service Market Restraints
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer